# A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

> **NCT01153815** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 170 (actual)

## Conditions studied

- Cerebrovascular Accident

## Interventions

- **DRUG:** GSK1358820(Botulinum toxin type A)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01153815
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153815, "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01153815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*